Guardant Health Inc Revenue Growth Rates (GH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Guardant Health Inc   (NASDAQ: GH)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

GH's Revenue Growth by Quarter and Year

Guardant Health Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 334.98
1st Quarter March 301.67
FY 636.65

GHs Annual Revenue
Guardant Health Inc 's Revenue in the fiscal year 2025 $ 982.02 millions
Guardant Health Inc 's Revenue in the fiscal year 2024 $ 739.02 millions
Guardant Health Inc 's Revenue in the fiscal year 2023 $ 563.95 millions
Guardant Health Inc 's Revenue in the fiscal year 2022 $ 449.54 millions
Guardant Health Inc 's Revenue in the fiscal year 2021 $ 373.65 millions




GH Revenue second quarter 2026 Y/Y Growth Comment
Guardant Health Inc achieved in the second quarter 2026, above Company average Revenue rise of 44.33% year on year, to $ 334.98 millions.

Looking into second quarter 2026 results within Medical Laboratories industry 20 other companies have achieved higher Revenue growth. While Guardant Health Inc ' s Revenue jump of 44.33% ranks overall at the positon no. 1800 in the second quarter 2026.


GH Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 39.37 % 30.16 % 22.19 %
3rd Quarter September - 38.5 % 33.87 % 21.83 %
2nd Quarter June 44.33 % 30.95 % 29.23 % 25.66 %
1st Quarter March 48.26 % 20.76 % 30.91 % 33.93 %
FY   - 32.88 % 31.05 % -

Financial Statements
Guardant Health Inc 's second quarter 2026 Revenue $ 334.98 millions GH's Income Statement
Guardant Health Inc 's second quarter 2025 Revenue $ 232.09 millions Quarterly GH's Income Statement


GH Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 6.06 % 5.39 % 8.4 %
3rd Quarter September - 14.27 % 8.03 % 4.29 %
2nd Quarter June 11.04 % 14.07 % 5.19 % 6.56 %
1st Quarter March 7.25 % 0.82 % 8.67 % 1.43 %
FY (Year on Year)   - 32.88 % 31.05 % -


Back to GH Growth rate Comparisons >> Back to GH Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #21
Healthcare Sector #283
Overall #1800

Revenue Y/Y Growth Statistics
High Average Low
167.57 % 42.98 % 20.31 %
(Sep 30 2019)   (Dec 31 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #21
Healthcare Sector #283
Overall #1800
Revenue Y/Y Growth Statistics
High Average Low
167.57 % 42.98 % 20.31 %
(Sep 30 2019)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Guardant Health Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
51.54 % 10.05 % -11.11 %
(Dec 31 2018)  


GH's II. Quarter Q/Q Revenue Comment
Guardant Health Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 11.04%, to $ 334.98 millions, from $301.67 millions in the first quarter.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Guardant Health Inc 's Revenue growth quarter on quarter, overall rank is 771.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #123
Overall #771
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #123
Overall #771
Revenue Q/Q Growth Statistics
High Average Low
51.54 % 10.05 % -11.11 %
(Dec 31 2018)  


GH's II. Quarter Q/Q Revenue Comment
Guardant Health Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 11.04%, to $ 334.98 millions, from $301.67 millions in the first quarter.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Guardant Health Inc 's Revenue growth quarter on quarter, overall rank is 771.


Guardant Health Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,183.11 $ 1,080.22 $ 982.02 $ 902.57 $ 828.85
Y / Y Revenue Growth (TTM) 42.74 % 39.56 % 32.88 % 30.38 % 28.74 %
Year on Year Revenue Growth Overall Ranking # 581 # 548 # 88 # 413 # 59
Seqeuential Revenue Change (TTM) 9.52 % 10 % 8.8 % 8.89 % 7.09 %
Seq. Revenue Growth (TTM) Overall Ranking # 1800 # 1975 # 522 # 1375 # 307


Cumulative Revenue growth Comment
Although Guardant Health Inc 's Annual Revenue growth year on year were below company's average 42.98% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.74% year on year, from 39.56% in Mar 31 2026.

In the Healthcare sector 128 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 548 to 581.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 21
Healthcare Sector # 129
Overall # 581

Revenue TTM Y/Y Growth Statistics
High Average Low
167.57 %
 42.98 %
20.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 283
S&P 500 # 1800
Cumulative Revenue growth Comment
Although Guardant Health Inc 's Annual Revenue growth year on year were below company's average 42.98% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.74% year on year, from 39.56% in Mar 31 2026.

In the Healthcare sector 128 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 548 to 581.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 21
Healthcare Sector # 129
Overall # 581

Revenue TTM Y/Y Growth Statistics
High Average Low
167.57 %
42.98 %
20.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 283
S&P 500 # 1800




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GH's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions


About Guardant Health Inc Revenue Growth Rates (GH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Guardant Health Inc (CIK 1576280).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001576280-26-000037
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Guardant Health Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.